GLP-1 Providers That Use 503A Pharmacies (April 2026, Verified)

Why You Searched for “503A” Specifically (and What That Tells Us)

Most people searching this exact phrase fall into one of three groups. You probably recognize yourself.

All three groups need the same thing: a clean list of which legitimate providers are operating in the 503A lane in April 2026, who names their partners, who doesn’t, and how to verify the answer in five minutes before paying. That’s what this page is.

What a 503A Pharmacy Actually Is (in Plain English)

A 503A pharmacy is a state-licensed compounding pharmacy that prepares medications for individual patients based on prescriptions. The “503A” comes from Section 503A of the federal Food, Drug, and Cosmetic Act — the law that carved out a legal pathway for traditional pharmacy compounding back in 1997, then strengthened it after the 2012 New England Compounding Center contamination tragedy that killed 64 people. State boards of pharmacy regulate 503A facilities. The FDA can also act on them, but day-to-day oversight is state-level.

For compounded GLP-1s specifically — semaglutide and tirzepatide — the FDA says that for products that would otherwise be “essentially copies” of commercially available brand-name drugs, the prescriber must determine and document a significant difference for the identified patient. That patient-specific clinical justification is what separates a defensible 503A compounded GLP-1 prescription from one that’s vulnerable to enforcement action.

Three things 503A is not:

1. Not FDA-approved. The finished compounded product doesn’t go through FDA review for safety, effectiveness, or quality. Any provider that tells you otherwise is misrepresenting the law.
2. Not a generic. Generics are FDA-approved copies of brand-name drugs whose patents have expired. Compounded semaglutide is not a generic Ozempic. Compounded tirzepatide is not a generic Mounjaro. The FDA has issued dozens of warning letters specifically targeting “same active ingredient” and “generic Wegovy” marketing language.
3. Not the same as 503B. A 503B outsourcing facility is FDA-registered, follows current Good Manufacturing Practice (cGMP) standards similar to a manufacturer, and can produce larger batches without an individual prescription — but only when the drug is on the FDA shortage list or appears on the 503B Bulks List. Semaglutide and tirzepatide are on neither list as of April 2026, which is why most 503B facilities exited the GLP-1 space.

The honest tradeoff: 503B has stricter manufacturing oversight when it’s allowed to operate. 503A has the patient-specific clinical pathway that survives a resolved drug shortage. For compounded GLP-1s in 2026, 503A is the more durable legal pathway — which is why the compounded telehealth providers worth shortlisting in this category are the ones operating through one or more disclosed 503A pharmacy partners.

What pharmacy language actually proves (and what it doesn’t)

This table is the lens. Read every provider’s pharmacy page through it.

Is Compounded GLP-1 From a 503A Pharmacy Still Legal in 2026?

Yes — but the door is narrower than it was, and providers who advertise like it’s still 2024 are headed for a warning letter.

Here’s the timeline that matters:

That April 1, 2026 clarification is the one that changed how legitimate providers operate now. The FDA said two things that matter to you:

1. A 503A pharmacy can’t regularly or in inordinate amounts compound something that’s “essentially a copy” of a commercially available drug. The agency specifically called out semaglutide combined with vitamin B12 — if the strengths are within 10% of the brand product, FDA considers it essentially a copy.
2. The FDA stated it does not currently intend to take action against a 503A compounder filling four or fewer prescriptions per calendar month for any one “essentially a copy” formulation. (This is current FDA enforcement intent, not a permanent statutory carve-out.)

Translation: a real 503A operation in 2026 prepares patient-specific medications based on individualized clinical justification — usually one of three documented pathways:

• Documented allergy to an inactive ingredient in the FDA-approved product (e.g., polysorbate 80).
• Dose strength not commercially available — a microdose, a step-up titration strength the brand doesn’t sell, or a custom strength the prescriber documents as clinically necessary.
• Different delivery route — sublingual, oral drops, or dissolvable tablets when the patient cannot self-inject.

If your provider’s intake form took 90 seconds and the output was a generic “personalized formulation,” that’s not the same thing as a clinician documenting a specific clinical reason an FDA-approved drug doesn’t fit your case. We’ll show you how to tell the difference in the verification section below.

Sources: FDA, “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize” (last updated April 2026); FDA Warning Letters database; Foley & Lardner, “FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products” (April 2026); Wilson Sonsini, “FDA Sends Warning Letters to More Than 50 GLP-1 Compounders” (October 2025); Reuters, March 2026 Novo Nordisk/Hims & Hers settlement coverage.

Which GLP-1 Providers That Use 503A Pharmacies Name Their Pharmacy Partners?

Of the major telehealth platforms operating in or adjacent to the 503A compounded GLP-1 lane in April 2026, only a handful publicly identify which pharmacy will fill a patient’s prescription. Two affiliate-eligible providers met our disclosure standard for this page: Enhance.MD names three pharmacy partners in its public terms of service, and Eden references U.S.-licensed 503A pharmacies plus its acquired Contigo Compounding facility. The rest either stop at “our network of licensed compounding pharmacies” or carry FDA warning letters that disqualify them from a top-tier recommendation on a page about pharmacy compliance.

The matrix below is the one no other comparison article publishes. Every cell is dated, sourced, and re-verified monthly.

The 503A GLP-1 Provider Transparency Matrix (April 2026)

The Full Provider Breakdown

4. Honest Disclosures: Providers With FDA Warning Letters

Three providers we’d otherwise rank in the affiliate-eligible tier carry active FDA warning letters as of our verification date. We’re disclosing them in plain language because the alternative — leaving them off this page entirely or hiding the regulatory facts — would help us in the short term and hurt you. On a page literally about pharmacy compliance, the warning letters are the story.

We’re not linking to any of these three providers from this page. If you want to evaluate them further, you can find them directly. Our job here is to make sure you have the regulatory information that should inform that decision.

Sources: FDA Warning Letter to Matthew Stern, CEO MyStart Health LLC (#714755, September 9, 2025); FDA Warning Letter to Direct Meds (September 9, 2025); FDA Warning Letter to MEDVi, LLC dba MEDVi (#721455, February 20, 2026); FDA, “FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s” (March 3, 2026).

5. The “Verify Before Paying” Tier

These providers use compounding language but didn’t surface explicit, verifiable Section 503A disclosure in materials we sampled, and they don’t carry FDA warning letters in our review. That doesn’t make them illegitimate. It means the verification step is on you before you pay. Use the 7-question script in the next section.

• Yucca Health — strong async, low-friction value path with clear “as low as” pricing and BNPL options like Klarna. Licensed pharmacy language confirmed; explicit 503A status not confirmed in sampled materials. Best fit for value shoppers who’ll send the verification email.
• bmiMD — describes medication as formulated within a licensed State Board of Pharmacy compounding facility, says it works with licensed sterile compounding pharmacies, and discloses that compounded medications are not FDA-approved. Microdose-style positioning. Explicit 503A status not confirmed in sampled materials.
• Willow — flat $299/month positioning, licensed compounding pharmacy language. Explicit 503A status not confirmed. Material context: Willow was named in April 2025 Eli Lilly compounded-tirzepatide litigation; the case was reportedly dismissed in September 2025. Confirm current docket status before relying on this.
• SHED — publishes detailed educational content on 503A vs 503B in its blog, but the specific dispensing pharmacy for an individual prescription wasn’t named in materials we reviewed. Best fit for needle-averse readers if support confirms a 503A partner for your state and formulation.

For all four, the verification approach is the same: send the 7-question script below before checkout. Clean answer? You can proceed. Vague language (“our network of licensed pharmacies”)? You have your answer.

Pharmacies You’ll See Named (and What to Know About Each)

The most common compounding pharmacies that come up in real GLP-1 conversations — Reddit threads, BBB complaint patterns, provider FAQs — are these. Treat this section as a name-recognition primer, not a recommendation list. The pharmacy itself isn’t what you choose; you choose a provider that uses a pharmacy.

• TruMedsRx — Fairfax, Virginia. Licensed in 48 states. Self-described as a 503A compounding mail-order pharmacy serving 85,000+ patients. One of Enhance.MD’s three named partners.
• Vios Compounding Pharmacy — Livonia, Michigan. One of Enhance.MD’s three named partners.
• Rite-Away Pharmacy — San Antonio, Texas. One of Enhance.MD’s three named partners.
• Contigo Compounding — Eden-acquired 503A compounding pharmacy, branded as Eden Pharmacy. Licensed in 25 states.
• Strive Pharmacy — A 503A compounding pharmacy with notable industry transparency: per its public “Higher Standards” page, Strive describes voluntary PCAB and NABP accreditation, weekly randomized batch testing, a stated ±3% potency variance target (industry standard is ±10%), and a stated 99.9%+ sterility/endotoxin pass rate. Strive is named as Thrive by Mira’s pharmacy partner. Material concern: Eli Lilly filed litigation against Strive Pharmacy related to compounded tirzepatide formulations. The litigation was active as of January 2026 and should be re-checked on the federal docket before relying on Strive as your fulfillment pharmacy.
• PerfectRx/PerfectionRx, ProRx, Casa, Pharmacy Hub, SmartPharmaRx — Named as 503A pharmacy partners by OrderlyMeds in its public FAQ.
• Empower Pharmacy — Operates both 503A and 503B operations. Empower’s GLP-1 page describes 503A PCAB-accredited compounding capability. Empower is a direct pharmacy source rather than a consumer-facing telehealth provider; you’re more likely to see it referenced through a clinical platform than to use it directly.
• Hallandale Pharmacy — Frequently mentioned in Reddit GLP-1 threads and in past partnerships with various telehealth platforms. Operates as a 503A. Material concern: Hallandale received an FDA warning letter in 2020 for sterility violations at a previous facility location. Customer review patterns are mixed.
• Belmar Pharma Solutions — Six facilities in Colorado and Florida, four decades of operating history. Named in pharmacy networks used by some platforms.
• Boothwyn Pharmacy — Received an FDA warning letter on January 16, 2026 for insanitary conditions and strength/quality/purity noncompliance on compounded GLP-1 products. Avoid any platform that names Boothwyn as its current dispensing pharmacy.

If a provider’s support team names a pharmacy you don’t recognize, the verification path is straightforward: search the FDA Warning Letters database, look up the pharmacy on the relevant state board of pharmacy license database, and check the NABP Safe Site Search directory. We walk through the exact steps in the next section.

How to Verify a 503A Pharmacy in Five Minutes (the 7-Question Script)

This is the part you save for later. It’s the most useful single asset on this page, and it works for any GLP-1 provider — not just the ones we ranked. Send this exact script to the provider’s support team before you enter payment information. Save the response. If anything ever goes wrong with your prescription, you’ll have written documentation of what was promised at signup.

If the answer comes back with a named pharmacy, a clear 503A or 503B label, a state license number you can verify on a state board of pharmacy lookup, and reasonable replacement and cancellation terms, you’re working with a legitimate operation and you can proceed.

If the answer comes back with vague language like “our network of licensed pharmacies” or “we work with FDA-registered facilities” without specifics, or if the response avoids one or more questions, that is information. You don’t have to draw a hostile conclusion — just acknowledge that you don’t have the disclosure you asked for, and decide whether to proceed without it or switch to a more transparent provider.

The four government and accreditation tools to keep open in browser tabs while you do this:

1. FDA Warning Letters database — fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters. Search the pharmacy name. If a warning letter exists in the past three years, it’ll surface here.
2. State Board of Pharmacy License Lookup — every U.S. state maintains one. Search “[state name] board of pharmacy license lookup.” Confirm the pharmacy holds an active, unrestricted license.
3. NABP Safe Site Search — safe.pharmacy/buy-safely/. The National Association of Boards of Pharmacy maintains a directory of accredited online pharmacies (VIPPS) and a “Not Recommended” list of sites that fail their safety standards.
4. FDA BeSafeRx — fda.gov/drugs/buying-using-medicine-safely/besaferx-your-source-online-pharmacy-information. The FDA’s consumer-facing guidance for verifying online pharmacy safety, including the warning signs of an illegal operation.

The whole verification takes under five minutes once you know where to look. You only ever have to do this once per provider — if they pass, you’re done. If they fail, you saved yourself $200–$400/month and an unknown amount of regulatory headache.

When 503A Compounded Isn’t Right For You: The FDA-Approved Path

There are specific situations where compounded 503A GLP-1 — even with a great provider and a verified pharmacy — is the wrong choice. We’d rather lose you to a more appropriate path than convert you to a fit you’d reverse later.

Choose an FDA-approved brand-name path if any of these apply:

• You have insurance. Many commercial plans cover branded GLP-1s outright (especially for Type 2 diabetes indications) or cover them after a prior authorization. The cost difference between an insured Wegovy or Zepbound prescription and self-paying $200/month for compounded is usually substantial, and copays vary widely by plan.
• Your clinical situation doesn’t map to a 503A justification pathway. If you have no documented allergy to inactive ingredients, you don’t need a non-commercial dose strength, and you can self-inject — your case doesn’t have a defensible clinical reason to choose compounded over FDA-approved. A provider that approves you anyway is taking on regulatory risk you’ll inherit.
• You want regulatory certainty. Compounded products are not FDA-reviewed. If you don’t want to think about pharmacy partnerships, warning letters, or court rulings, FDA-approved is the path that lets you stop thinking about all of it.
• You’re risk-averse with novel medications. GLP-1s themselves are well-studied at this point, but compounded versions add a second layer of variability (sourcing, sterility, formulation) that the brand product doesn’t carry.

Brand-name options to ask about:

• Wegovy (semaglutide) — FDA-approved for chronic weight management. Available as a pen and a once-daily pill.
• Zepbound (tirzepatide) — FDA-approved for chronic weight management; also has an FDA-approved indication for moderate-to-severe obstructive sleep apnea added in December 2024.
• Foundayo™ (orforglipron) — newer FDA-approved oral GLP-1 for chronic weight management.
• Ozempic (semaglutide) — FDA-approved for Type 2 diabetes; sometimes prescribed off-label for weight loss when clinically appropriate.
• Mounjaro (tirzepatide) — FDA-approved for Type 2 diabetes; may be prescribed off-label for weight management. Note that Mounjaro is not currently available through Ro Body — Zepbound is the tirzepatide brand Ro lists for weight loss.

Ro Body is the program we recommend most often for this lane because of menu breadth and the insurance concierge. As of April 2026: $39 first month, then as low as $74/month with annual prepay or $149/month month-to-month, with medication billed separately. If you’re insurance-eligible, the free GLP-1 Insurance Coverage Checker is the highest-value step you can take before paying for self-pay anything.

For the boxed warning and contraindication details on any FDA-approved GLP-1 — including the warnings for personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — refer to the FDA prescribing information for the specific product (Wegovy, Zepbound, Foundayo, Ozempic, Mounjaro). A clinician should review your individual risk profile.

For FDA-approved telehealth options beyond Ro, see our deeper guide to the best brand-name GLP-1 telehealth providers.

Honest Risks of 503A Compounded GLP-1s

Three categories of risk apply to compounded 503A GLP-1s that don’t apply (or apply less) to FDA-approved brand-name medication. Knowing these isn’t a reason to walk away — it’s a reason to choose carefully.

Risks that don’t change between brand and compounded. Every GLP-1 user faces the same drug-class side effect profile regardless of source: nausea, vomiting, diarrhea, and constipation are the common ones, dose-dependent. Less common but serious risks include pancreatitis and gallbladder disease. GLP-1 medications carry boxed warnings for personal or family history of MTC or MEN 2 — refer to the FDA prescribing information for any specific product (Wegovy, Zepbound, Foundayo, Ozempic, Mounjaro) for the complete warning, contraindication, and adverse-reaction information. These are class-level concerns, not compounding-specific concerns. Talk to a clinician about your individual risk profile.

Sources: FDA, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss” (cumulative July 31, 2025 adverse-event figures); Eli Lilly published compounded-sample testing summary; Eli Lilly open letter (March 12, 2026); Foley & Lardner, “FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products” (April 2026); Holland & Knight, “Eli Lilly Strikes Back Against Pharmacy Compounders and Telehealth Platforms” (June 2025).

What We Actually Verified for This Page

We’re putting our work where you can see it. Every claim above traces to one of these sources, accessed on or before the verification date at the top of this page.

Verified from public records (April 29, 2026):

• FDA April 1, 2026 “essentially a copy” clarification language and the four-prescription enforcement intent
• FDA Warning Letter #721455 to MEDVi, dated February 20, 2026 (FDA Warning Letters database)
• FDA Warning Letter #714755 to Matthew Stern, CEO MyStart Health LLC, dated September 9, 2025
• FDA Warning Letter to Direct Meds, dated September 9, 2025
• FDA Warning Letter to Boothwyn Pharmacy, January 16, 2026
• FDA shortage resolution timeline (tirzepatide initially Oct 2, 2024; re-evaluated Dec 19, 2024; semaglutide Feb 21, 2025) and enforcement-discretion deadlines
• Enhance.MD’s named pharmacy partners (Rite-Away, Vios, TruMedsRx) per published terms of service
• Eden’s acquisition of Contigo Compounding and public 503A pharmacy language; Eden Pharmacy 25-state licensed footprint
• OrderlyMeds’ named pharmacy partners (PerfectRx/PerfectionRx, ProRx, Casa, Pharmacy Hub, SmartPharmaRx) per public FAQ
• Strive Pharmacy’s published quality standards (PCAB and NABP voluntary accreditations, weekly batch testing, stated ±3% potency variance, stated 99.9%+ sterility/endotoxin pass rate) per Strive’s public “Higher Standards” page
• Strive Pharmacy named in active Eli Lilly compounded-tirzepatide litigation
• Ro Body’s current pricing structure ($39 first month, as low as $74/month annual prepay, $149/month month-to-month) and FDA-approved menu (Wegovy pill, Foundayo pill, Zepbound KwikPen, Wegovy pen, Ozempic, eligible insurance options) per Ro’s public pricing page
• Ro’s stated government-insurance limitation (with FEHB exception)
• FDA cumulative adverse-event reports for compounded GLP-1 as of July 31, 2025
• Active litigation across Novo Nordisk, Eli Lilly, and Outsourcing Facilities Association court filings; Novo/Hims March 2026 settlement

Not independently verified (stated as provider claims rather than confirmed facts):

• Each provider’s internal clinical-justification documentation process (we report what providers publicly disclose; we cannot inspect intake records)
• Specific dispensing pharmacy for a given state and formulation (this varies — confirm via the 7-question script before paying)
• Real-time supply continuity at any pharmacy partner (changes weekly)
• Whether the website language flagged in MyStart, Direct Meds, or MEDVi warning letters has been corrected as of this verification date
• Each named pharmacy’s current USP 797 sterility test results (request testing documentation from the provider for verification)
• Current Willow litigation docket status (case reportedly dismissed September 2025; verify before relying)

[needs verification] markers anywhere in this page indicate cells we couldn’t independently confirm as of the verification date. We update those on the monthly scan.

Frequently Asked Questions

Bottom Line: Which 503A GLP-1 Provider Should You Start With?

If you’ve read this far, you’re not the reader who needs to be sold. You’re the reader who needs the right answer.

• Start with Enhance.MD if your top priority is named pharmacy partner transparency. They list three 503A pharmacies in their terms of service, which is more disclosure than any other affiliate-eligible compounded platform offers.
• Start with Eden if you want a broad, mainstream self-pay program with flat-rate pricing and a vendor that owns part of its own pharmacy supply chain through Contigo Compounding.
• Start with Ro Body if compounded medication’s regulatory uncertainty isn’t worth the cost difference for you. $39 first month, then as low as $74/month with annual prepay (medication billed separately), with FDA-approved Wegovy, Foundayo, Zepbound, and other branded options — and an insurance concierge that may save you most of your medication cost if you’re covered.
• Take the matching quiz if you genuinely don’t know which lane fits — compounded vs. FDA-approved, injectable vs. oral, insurance vs. self-pay. The quiz takes 60 seconds and routes you to a specific recommendation. We don’t ask for a phone number and we don’t sell anything except your own clarity.

Whatever you choose, do the verification step before you pay. The 7-question script is the most useful five minutes you’ll spend in this entire research process. Save it. Use it on every provider, including the ones we recommended. We’d rather you trust our process than trust us blindly.

Your next-step options:

For named-pharmacy transparency · for broad self-pay programs · for FDA-approved instead.

About This Page

Sources

1. U.S. Food and Drug Administration. "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize." Updated April 2026.
2. U.S. Food and Drug Administration. "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss."
3. U.S. Food and Drug Administration. Warning Letter #721455 to MEDVi, LLC dba MEDVi, February 20, 2026.
4. U.S. Food and Drug Administration. Warning Letter #714755 to Matthew Stern, CEO MyStart Health LLC, September 9, 2025.
5. U.S. Food and Drug Administration. Warning Letter to Direct Meds, September 9, 2025.
6. U.S. Food and Drug Administration. "FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s." March 3, 2026.
7. U.S. Food and Drug Administration. "BeSafeRx: Your Source for Online Pharmacy Information."
8. National Association of Boards of Pharmacy. "Find Safe Online Pharmacies." safe.pharmacy
9. Foley & Lardner. "FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products." April 2026.
10. Spencer Fane. "FDA and Novo Nordisk Warn of GLP-1 Telehealth Compounding Take Down — What's Next?" February 2026.
11. Wilson Sonsini. "FDA Sends Warning Letters to More Than 50 GLP-1 Compounders and Manufacturers." October 2025.
12. Pharmacy Times. "FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown. What's Next?" 2026.
13. Holland & Knight. "Eli Lilly Strikes Back Against Pharmacy Compounders and Telehealth Platforms." June 2025.
14. Buchanan Ingersoll & Rooney PC. "Oral Semaglutide and the GLP-1 Compounding Reckoning." February 2026.
15. Frier Levitt. "The Return of 503B Compounding of GLP-1 Medications." January 2026.
16. Alliance for Pharmacy Compounding. "Compliance alert: 503Bs and GLP-1 compounding." 2025.
17. Strive Pharmacy. "Higher Standards." strivepharmacy.com/higher-standards
18. Ro. "Weight Loss Program Pricing." ro.co/weight-loss/pricing
19. Reuters. "Novo Nordisk and Hims & Hers reach agreement; lawsuit dropped." March 2026.
20. Enhance.MD. Terms of Service (named pharmacy partners).